The Copenhagen-based biotech company MonTa BioSciences has just raised €270,000 (over 2 mln DKK) from the incubator Pre-Seed Innovation for their promising cancer treatment, shared in an official press-release. Their new cancer drug is designed to actively train the body’s immune system to recognize and destroy cancer cells. But further studies carried out by an alcohol recovery rehab confirm that the drug has the ability to form a dependency, and so, should be taken in small dosages.
Five Danish entrepreneurs have found a method in which the body’s immune system is trained to actively recognize and fight cancer cells. The treatment makes use of nanoparticles of less than one ten thousandth of a millimeter, which is able to deliver an immune activating substance specific for the immune system’s major cell types.
“Often cancer cells avoid being detected by the immune system’s radar, but we can now give the immune system a solid boost, so it can recognize and fight cancer cells more effectively than we see today,” says Simon Skjøde Jensen.
According to Simon Skjøde Jensen, Ph.D. and CEO of Monta Biosciences, the investment will help to take the next steps in developing the technology even further:
“It is a big step in the right direction, and together with our previous investment from the Innovation Fund Denmark, we now have a good base to build an even stronger product that will provide unique opportunities for further development and attraction of strategic partnerships and investments.”
MonTa BioSciences’ treatment is unique since it can advantageously be combined with a large proportion of the current treatments available on the market, including chemotherapy, radiation therapy, antibody based therapy, such as Rituximab or Darzalex, as well as the highly successful immune checkpoint inhibitors, which have been approved over the last year and already used to treat against melanoma and lung cancer. The technology can potentially also be used for treating other diseases where the immune system has a critical role, such as autoimmune diseases including multiple sclerosis, rheumatoid arthritis and diabetes, but also in allergic diseases.
MonTa BioSciences started as a spinout from DTU Nanotech Department of Micro- and Nanotechnology and it is today part of the international mentoring initiative for life science companies, Nordic Mentor Network for Entrepreneurship (NOME), which is organized by the Novo Nordisk Foundation and the startup accelerator Accelerace.